Home/Pipeline/HMPL-760

HMPL-760

B-cell Malignancies

Phase 1Active

Key Facts

Indication

B-cell Malignancies

Phase

Phase 1

Status

Active

Company

HUTCHMED

About HUTCHMED

HUTCHMED is a leading, innovation-driven biopharma focused on oncology and immunology, with a strategy of 'in China, for the world.' The company has successfully brought novel drugs like fruquintinib (ELUNATE®) to market in China and achieved its first global approval with Takeda. Its business model integrates discovery, development, manufacturing, and commercialization, supported by a deep pipeline of both internally discovered and in-licensed assets. HUTCHMED aims to become a global biopharmaceutical leader by advancing its pipeline through strategic global partnerships.

View full company profile

Therapeutic Areas

Oncology Immunology

Other B-cell Malignancies Drugs

Drug	Company	Phase	Status
Pirtobrutinib	Eli Lilly	Phase 3	Active
Mezagitamab	Kyowa Kirin	Phase 1/2	Active
Velexbru (tirabrutinib)	Ono Pharmaceutical	Phase 3	Active
KT-413	Kymera Therapeutics	Phase 1	Active
TG-1701	TG Therapeutics	Phase 1	Early-stage (based on general knowledge)
TG-1801	TG Therapeutics	Phase 1	Early-stage (based on general knowledge)
REC-3565	Recursion Pharmaceuticals	Phase 1	Active
UCART20x22	Cellectis	Phase 1/2	Active (in collaboration with Servier)
FT819	Fate Therapeutics	Phase 1	Active
Prulacabtagene leucel (prula-cel, ADI-001)	Adicet Bio	Phase 1	Previously Studied